Today I had a chat with Nigel Theabold CEO of N4 Pharma, the small private company hit the headlines when Aim listed investment company Onzima Ventures announced its investment for 49% of the company. The business works extensively on a number of compounds through the early development stage, with a novel structure which reduces significant dilution whilst focusing on progressing quickly into presenting its products through its technology platform.
Business model to reformulate and develop erectile dysfunction drugs
Strong background in product development working with Oxford Pharma Science
New clinical and commercial products into the forefront of industry
Regular focus on news flow with as the exciting outlook surfaces further